

P & T Committee Policy for Public Comment

A. Public comment during the P & T Committee Meeting is limited to representatives from the pharmaceutical industry and is not open to the general public, representatives of advocacy/special interest groups or members of academic organizations unless such individual is designated to speak on behalf of the industry by the industry.

B. Content is limited to drugs relevant to the drug classes on the agenda to be discussed during the meeting.

C. Speakers must sign in at least ten (10) minutes prior to the start of the meeting; otherwise the speaker will not be permitted to speak during the public comment period.

D. Presentations

(1) The Chair will recognize the speakers according to the order in which they are listed on the sign in sheet.

(2) Speakers may only provide oral presentations; no visual or audio aids may be used.

(3) Per the request of the Committee, no written documents or handouts are to be provided to Committee members prior to and/or during meeting.

(4) Speakers shall limit their presentation to three (3) minutes per drug/per class/per manufacturer.

(5) The presentation should focus on the clinical advantages of the particular product and should refrain from criticizing the products from other competitors.

G. No questions or comments from the audience will be entertained unless approval is granted by two-thirds of the members present at the meeting.

H. The Committee reserves the right to suspend or eliminate the period for public comment if the privilege becomes abused or is deemed to be non-productive.